Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab in mild to moderate Alzheimer's disease
NCT00905372Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2009
- Primary completion
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of solanezumab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started May 2009; status: completed.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00905372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00905372.